Sarilumab (SAR) + 14 wk GC taper demonstrated significant efficacy vs the comparator arm in steroid refractory PMR patients and improvement in quality of life. Sustained remission was 28.3% SAR vs 10.3% comparator arm. Spiera R Abs#1676 https://t.co/gXGJzbYLHK #ACR22 @RheumNow https://t.co/oZBsRtxMUw

• Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multice…

#abst1679 #acr22 @rheumnow CARRA STOP-JIA early introduction of bDMARD beneficial in polyarticular JIA: in early combination of cDMARD+biologic group > pts able to achieve Clinical Remission& significantly longer T spent in CID& cJADAS10 ID during the 3 year study vs step up Rx https://t.co/xwQJnSeCNE

L05 #ACR22 High-dose Denosumab in Erosive Hand OA 48Wk, Double-blind PBO Phase 2 100 patients GUSS change higher in DEN v PBO at w24, incr at w48 New erosions lower in DEN w48 (2% v 7%, OR 0.23, p<0.001) Open label extension w improvement to baseline @RheumNow https://t.co/X6MF9q2bKj

Castrejon et al. Cancer risk with b/tsDMARD in BIOBADASER. Again not looking great for abatacept, Rate ratio vs TNFi 2.2 (1.4-3.2). Age-adjusted HR 1.6 (1.0-2.6) @RheumNow #ACR22 Abstr#1752 https://t.co/PvBq2O9qPv https://t.co/XBfistBMhW

• Cancer Risk in Patients with Rheumatic Diseases Exposed to Different Biologic a…

Baraliakos et al. AEs with SC vs IV infliximab. Relatively comparable safety profiles. Higher administration site reactions in SC. @RheumNow #ACR22 Abstr#1769 https://t.co/KnYlvifDlr https://t.co/VnKOYs86Xz

• Comparative Evaluation of Adverse Events Associated with Subcutaneous Inflixima…

In RA pts initiating their first b/tsDMARD, Abs 1420 did not observe differences in 6- and 12-month effectiveness outcomes between ETN, ADA, and JAKi monotherapy. #ACR22 @RheumNow https://t.co/e8GA45Rrmd https://t.co/zooGxlTftO

• Outcomes in Patients with Rheumatoid Arthritis Initiating Monotherapy with Etan…

Baker et al, Corevitas registry in 7000+ RA pts Pts w/ moderate pain HR 1.37 Pts w/ severe pain HR 1.42 more likely to switch to diff MOA b/tsDMARD Adjusted for confounders incl DA Time we address pain separately to spare MAOs in a lifelong disease! Abs#1590 #ACR22 @Rheumnow https://t.co/RP8Rb6bp9m